Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Nora AI
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Press release

BioStock Investor Pitch: Alligator Bioscience

Alligator Bioscience

Alligator Bioscience has been off to a hot start in 2023. First came the positive interim results from the phase II study in pancreatic cancer. Then, the first patient was dosed in a phase I study for the treatment of solid tumours in a collaboration with Aptevo Therapeutics. Now the company is carrying out a rights issue of approximately 199 million SEK. Alligator's CEO Søren Bregenholt tells us more about ongoing activities in a BioStock Investor Pitch today at 09.15 am. 

Watch the presentation by Søren Bregenholt at biostock.se:

https://www.biostock.se/en/2023/05/biostock-investor-pitch-alligator-bioscience/
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

This material has been prepared for marketing purposes and is not and should not be considered a prospectus under applicable laws and regulations. The full terms and conditions of the rights issue and more information about the company have been presented in the EU Growth Prospectus published at alligatorbioscience.se (https://alligatorbioscience.se/en/) on 26 April 2023. The EU Growth Prospectus has been approved and registered by the Financial Supervisory Authority. The marketing material is not intended to replace the EU growth prospectus as a basis for decisions to subscribe to shares in Alligator Bioscience and does not constitute a recommendation to subscribe to shares in Alligator Bioscience. Investors intending or considering investing in Alligator Bioscience are therefore advised to read the EU growth prospectus.

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.